Chinmayee Dash

Chinmayee Dash

Auto-generated profile, based on publicly available information

Chinmayee Dash

The Morningside Graduate School of Biomedical Sciences at the UMass Chan Medical School 5 , Worcester, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
TSTanmoy Saha
Tanmoy Saha
CDChinmayee Dash
Chinmayee Dash
RJRuparoshni Jayabalan
Ruparoshni Jayabalan
SKSachin Khiste
Sachin Khiste
AKArpita Kulkarni
Arpita Kulkarni
SSShiladitya Sengupta
Shiladitya Sengupta

14 June 2024 in Science Advances
Verified
Journal Article
Open access
TSTanmoy Saha
Tanmoy Saha
MFMichaela Fojtů
Michaela Fojtů
ANAstha Vinay Nagar
Astha Vinay Nagar
LTLiya Thurakkal
Liya Thurakkal
BSBalaaji Baanupriya Srinivasan
Balaaji Baanupriya Srinivasan
SSShiladitya Sengupta
Shiladitya Sengupta
The use of immune checkpoint inhibitors, which activate T cells, is a paradigm shift in the treatment of non–small cell lung cancer. However, the overall response remains low. To address this limitation, here we describe a novel platform, termed antibody-conjugated drug-loaded nanotherapeutics (ADN), which combines immunotherapy and molecularly targeted therapy. An ADN was designed with an anti-CD47 and anti–programmed death ligand 1 (PDL1) antibody pair on the surface of the nanoparticle and a molecularly targeted inhibitor of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of rapamycin) pathway, PI103, entrapped in the nanoparticle. The anti–CD47-PDL1-ADN exhibited greater antitumor efficacy than current treatment options with a PDL1 inhibitor in vivo in an aggressive lung cancer immunocompetent mouse model. Dual antibody-drug–loaded nanotherapeutics can emerge as an attractive platform to improve outcomes with cancer immunotherapy.

Verified
Journal Article
Open access
PDF file
CDChinmayee Dash
Chinmayee Dash
TSTanmoy Saha
Tanmoy Saha
SSShiladitya Sengupta
Shiladitya Sengupta
HJHae Lin Jang
Hae Lin Jang
The interaction of tumor cells with blood vessels is one of the key steps during cancer metastasis. Metastatic cancer cells exhibit phenotypic state changes during this interaction: (1) they form tunneling nanotubes (TNTs) with endothelial cells, which act as a conduit for intercellular communication; and (2) metastatic cancer cells change in order to acquire an elongated phenotype, instead of the classical cellular aggregates or mammosphere-like structures, which it forms in three-dimensional cultures. Here, we demonstrate mechanistically that a siRNA-based knockdown of the exocyst complex protein Sec3 inhibits TNT formation. Furthermore, a set of pharmacological inhibitors for Rho GTPase–exocyst complex-mediated cytoskeletal remodeling is introduced, which inhibits TNT formation, and induces the reversal of the more invasive phenotype of cancer cell (spindle-like) into a less invasive phenotype (cellular aggregates or mammosphere). Our results offer mechanistic insights into this nanoscale communication and shift of phenotypic state during cancer–endothelial interactions.

19 October 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
MSMunisha Smalley
Munisha Smalley
SNSiva Kumar Natarajan
Siva Kumar Natarajan
JMJayanta Mondal
Jayanta Mondal
DBDouglas Best
Douglas Best
DGDavid Goldman
David Goldman
AGAaron Goldman
Aaron Goldman
Drug-induced resistance, or tolerance, is an emerging yet poorly understood failure of anticancer therapy. The interplay between drug-tolerant cancer cells and innate immunity within the tumor, the consequence on tumor growth, and therapeutic strategies to address these challenges remain undescribed. Here, we elucidate the role of taxane-induced resistance on natural killer (NK) cell tumor immunity in triple-negative breast cancer (TNBC) and the design of spatiotemporally controlled nanomedicines, which boost therapeutic efficacy and invigorate “disabled” NK cells. Drug tolerance limited NK cell immune surveillance via drug-induced depletion of the NK-activating ligand receptor axis, NK group 2 member D, and MHC class I polypeptide-related sequence A, B. Systems biology supported by empirical evidence revealed the heat shock protein 90 (Hsp90) simultaneously controls immune surveillance and persistence of drug-treated tumor cells. On the basis of this evidence, we engineered a “chimeric” nanotherapeutic tool comprising taxanes and a cholesterol-tethered Hsp90 inhibitor, radicicol, which targets the tumor, reduces tolerance, and optimally reprimes NK cells via prolonged induction of NK-activating ligand receptors via temporal control of drug release in vitro and in vivo. A human ex vivo TNBC model confirmed the importance of NK cells in drug-induced death under pressure of clinically approved agents. These findings highlight a convergence between drug-induced resistance, the tumor immune contexture, and engineered approaches that consider the tumor and microenvironment to improve the success of combinatorial therapy. Significance: This study uncovers a molecular mechanism linking drug-induced resistance and tumor immunity and provides novel engineered solutions that target these mechanisms in the tumor and improve immunity, thus mitigating off-target effects.

3 March 2026 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
SKSravya Kurapati
Sravya Kurapati
CSChangsik Shin
Changsik Shin
KSKrisztina Szabo
Krisztina Szabo
YLYu Liu
Yu Liu
AAAzree Z. Ashraf
Azree Z. Ashraf
MBMilena Bogunovic
Milena Bogunovic
Proper organization of the enteric nervous system (ENS) is critical for normal gastrointestinal (GI) physiology. Inflammatory bowel disease (IBD) disrupts key GI functions, including bowel motility. However, in many IBD patients, motility disorders persist even during remission, suggesting an irreversible ENS defect secondary to IBD. Here, we show that postinflammatory GI motility dysfunction arises from structural remodeling of the ENS, driven by a combination of neuronal loss and neurogenesis. During mucosal inflammation, enteric neurons upregulate CCL2 expression, facilitating the recruitment of monocytes into the myenteric plexus within the intestinal muscle. Monocyte-derived macrophages infiltrate the myenteric ganglia, contributing to excessive ENS remodeling and postinflammatory motility dysfunction. This neuroimmune axis is counterbalanced by a hypoxia-induced stress response in enteric neurons mediated by HIF1α. Enhancing the neuron-intrinsic hypoxia pathway limits ENS remodeling and preserves motility. In summary, this study presents a mechanistic model of postinflammatory GI motility dysfunction and proposes a therapeutic strategy to maintain ENS integrity and function during inflammation.

31 March 2023
Verified
Other
Open access
MSMunisha Smalley
Munisha Smalley
SNSiva Kumar Natarajan
Siva Kumar Natarajan
JMJayanta Mondal
Jayanta Mondal
DBDouglas Best
Douglas Best
DGDavid Goldman
David Goldman
AGAaron Goldman
Aaron Goldman
Drug-induced resistance, or tolerance, is an emerging yet poorly understood failure of anticancer therapy. The interplay between drug-tolerant cancer cells and innate immunity within the tumor, the consequence on tumor growth, and therapeutic strategies to address these challenges remain undescribed. Here, we elucidate the role of taxane-induced resistance on natural killer (NK) cell tumor immunity in triple-negative breast cancer (TNBC) and the design of spatiotemporally controlled nanomedicines, which boost therapeutic efficacy and invigorate “disabled” NK cells. Drug tolerance limited NK cell immune surveillance via drug-induced depletion of the NK-activating ligand receptor axis, NK group 2 member D, and MHC class I polypeptide-related sequence A, B. Systems biology supported by empirical evidence revealed the heat shock protein 90 (Hsp90) simultaneously controls immune surveillance and persistence of drug-treated tumor cells. On the basis of this evidence, we engineered a “chimeric” nanotherapeutic tool comprising taxanes and a cholesterol-tethered Hsp90 inhibitor, radicicol, which targets the tumor, reduces tolerance, and optimally reprimes NK cells via prolonged induction of NK-activating ligand receptors via temporal control of drug release in vitro and in vivo. A human ex vivo TNBC model confirmed the importance of NK cells in drug-induced death under pressure of clinically approved agents. These findings highlight a convergence between drug-induced resistance, the tumor immune contexture, and engineered approaches that consider the tumor and microenvironment to improve the success of combinatorial therapy.Significance:This study uncovers a molecular mechanism linking drug-induced resistance and tumor immunity and provides novel engineered solutions that target these mechanisms in the tumor and improve immunity, thus mitigating off-target effects.